Danaher Co. (NYSE:DHR – Free Report) – Leerink Partnrs cut their Q1 2025 EPS estimates for shares of Danaher in a research report issued on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings per share of $2.02 for the quarter, down from their previous estimate of $2.06. The consensus estimate for Danaher’s current full-year earnings is $7.50 per share. Leerink Partnrs also issued estimates for Danaher’s Q2 2025 earnings at $1.88 EPS, Q3 2025 earnings at $1.86 EPS, Q4 2025 earnings at $2.46 EPS, FY2025 earnings at $8.22 EPS and FY2026 earnings at $9.22 EPS.
Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year.
Get Our Latest Research Report on DHR
Danaher Stock Down 0.2 %
NYSE:DHR opened at $234.36 on Monday. The stock has a fifty day simple moving average of $246.23 and a 200-day simple moving average of $257.30. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market cap of $169.27 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. Danaher has a twelve month low of $222.53 and a twelve month high of $281.70.
Hedge Funds Weigh In On Danaher
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fort Pitt Capital Group LLC lifted its holdings in shares of Danaher by 3.2% in the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares during the period. Good Life Advisors LLC acquired a new position in Danaher in the third quarter valued at approximately $217,000. Oak Thistle LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $363,000. Harvest Portfolios Group Inc. grew its stake in shares of Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp increased its holdings in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- How to Use Stock Screeners to Find Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- 3 Healthcare Dividend Stocks to Buy
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- The 3 Best Blue-Chip Stocks to Buy Now
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.